HK1220125A1 - 拉喹莫德的透皮配方 - Google Patents

拉喹莫德的透皮配方

Info

Publication number
HK1220125A1
HK1220125A1 HK16108223.4A HK16108223A HK1220125A1 HK 1220125 A1 HK1220125 A1 HK 1220125A1 HK 16108223 A HK16108223 A HK 16108223A HK 1220125 A1 HK1220125 A1 HK 1220125A1
Authority
HK
Hong Kong
Prior art keywords
laquinimod
transdermal formulations
transdermal
formulations
Prior art date
Application number
HK16108223.4A
Other languages
English (en)
Inventor
Stefan Ralph
Mika Hans-Juergen
Pries Tanja
Schenk Dirk
Prohl Sabine
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HK1220125A1 publication Critical patent/HK1220125A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16108223.4A 2013-03-14 2016-07-13 拉喹莫德的透皮配方 HK1220125A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361781585P 2013-03-14 2013-03-14
PCT/US2014/026807 WO2014152009A1 (en) 2013-03-14 2014-03-13 Transdermal formulations of laquinimod

Publications (1)

Publication Number Publication Date
HK1220125A1 true HK1220125A1 (zh) 2017-04-28

Family

ID=50729775

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108223.4A HK1220125A1 (zh) 2013-03-14 2016-07-13 拉喹莫德的透皮配方

Country Status (8)

Country Link
US (1) US20160038435A1 (zh)
EP (1) EP2968203A1 (zh)
JP (1) JP2016513665A (zh)
CA (1) CA2900977A1 (zh)
HK (1) HK1220125A1 (zh)
IL (1) IL240557A0 (zh)
MX (1) MX2015010967A (zh)
WO (1) WO2014152009A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
WO2015138887A1 (en) * 2014-03-14 2015-09-17 Teva Pharmaceutical Industries Ltd. Transmucosal delivery of laquinimod by oral patches

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
BRPI0617477A2 (pt) 2005-10-19 2011-07-26 Teva Pharma mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
EP2035001B1 (en) 2006-06-12 2011-11-09 Teva Pharmaceutical Industries Limited Stable laquinimod preparations
PL2682120T3 (pl) 2007-12-20 2017-02-28 Teva Pharmaceutical Industries, Ltd. Stabilne preparaty lakwinimodu
BRPI0913518A2 (pt) 2008-09-03 2016-07-26 Teva Pharma composto, composição farmacêutica, e, método de tratamento de um distúrbio mediado por função imune
MX2011013902A (es) 2009-06-19 2012-02-23 Teva Pharma Tratamiento de esclerosis multiple con laquinimod.
ME02414B (me) 2009-07-30 2016-09-20 Teva Pharma Tretman kronove bolesti lakvinimodom
EP3064206B1 (en) 2009-08-10 2019-03-20 Active Biotech AB Treatment of huntington's disease using laquinimod
DE102010026879A1 (de) * 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
BR112012021905A2 (pt) 2010-03-03 2015-09-29 Teva Pharma tratamento de nefrite lúpica usando laquinimod
JP5819328B2 (ja) 2010-03-03 2015-11-24 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療
PT2542080T (pt) 2010-03-03 2016-11-16 Teva Pharma Tratamento de artrite causada por lúpus usando laquinimod
US8252993B1 (en) 2010-05-25 2012-08-28 Pioneer Hi-Bred International, Inc. Inbred maize variety PH18FN
AU2011274502A1 (en) 2010-07-09 2013-02-28 Teva Pharmaceutical Industries Ltd. 5-chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
SG10201505236YA (en) 2010-07-09 2015-08-28 Teva Pharma Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
WO2012078591A1 (en) 2010-12-07 2012-06-14 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Also Published As

Publication number Publication date
IL240557A0 (en) 2015-10-29
US20160038435A1 (en) 2016-02-11
CA2900977A1 (en) 2014-09-25
WO2014152009A1 (en) 2014-09-25
MX2015010967A (es) 2015-10-26
JP2016513665A (ja) 2016-05-16
EP2968203A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
IL287516A (en) Medicinal uses of empagliflozin
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
HK1213818A1 (zh) 依帕列淨的治療用途
HK1221416A1 (zh) 氧雜雙環庚烷和氧雜雙環庚烯的配製品
HRP20181710T1 (hr) Uporaba derivata benzimidazol-prolina
LT2981271T (lt) Empagliflozino terapinis panaudojimas
EP2961397A4 (en) TRANSDERMAL FORMULATIONS
ZA201602198B (en) Preparation of hydroxy-benzylbenzene derivatives
EP2971029C0 (en) PRODUCTION OF MALTOOLIGOSACCHARIDES
ZA201602831B (en) Use of lactones
IL240763B (en) The halopyrazoles as thrombin inhibitors
ZA201505830B (en) Formulations of organc compounds
PL3063152T3 (pl) Dogodne wytwarzanie n-podstawionych morfinan-6-oli z morfinan-6-onów
HK1220125A1 (zh) 拉喹莫德的透皮配方
HK1204916A1 (zh) 淫羊藿苷元的醫藥用途
HK1225971A1 (zh) 使用拉喹莫德治療青光眼
PL3071575T3 (pl) Wytwarzanie normorfinanów